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DOI 10.1002/ajmg.a.37812Many studies have attempted to establish the genotype–
phenotype correlation in Rett syndrome (RTT). Cardiorespi-
ratory measurements provide robust objective data, to
correlate with each of the different clinical phenotypes. It
has important implications for the management and treat-
ment of this syndrome. The aim of this study was to correlate
the genotype with the quantitative cardiorespiratory data
obtained by neurophysiological measurement combined
with a clinical severity score. This international multicenter
study was conducted in four European countries from 1999
to 2012. The study cohort consisted of a group of 132 well-
defined RTT females aged between 2 and 43 years with
extended clinical, molecular, and neurophysiological assess-
ments. Diagnosis of RTT was based on the consensus criteria
for RTT and molecular confirmation. Genotype–phenotype
analyses of clinical features and cardiorespiratory data were
performed after grouping mutations by the same type and
localization or having the same putative biological effect on
the MeCP2 protein, and subsequently on eight single recur-
rent mutations. A less severe phenotype was seen in females
with CTS, p.R133C, and p.R294X mutations. Autonomic
disturbances were present in all females, and not restricted
to nor influenced by one specific group or any single recur-
rent mutation. The objective information from non-invasive
neurophysiological evaluation of the disturbed central auto-
nomic control is of great importance in helping to organize
the lifelong care for females with RTT. Further research
is needed to provide insights into the pathogenesis of2016 The Authors. American Journal of Medical Genetics Partautonomic dysfunction, and to develop evidence-based
management in RTT.  2016 The Authors. American Journal of
Medical Genetics Part A published by Wiley Periodicals, Inc.
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Rett syndrome (RTT) is a neurological disorder affecting almost
exclusively females. It is caused by mutations in the gene encoding
the methyl CpG binding protein 2 (MECP2) [Hagberg et al., 1983;
Amir et al., 1999]. A unique pattern of neurological and behavioral
symptoms appears over time [Julu et al., 2008]. Most prominent
are the abnormal breathing patterns, which is a consequence of
developmental brainstem immaturity in this syndrome. Abnormal
breathing is the most distressing and underestimated feature in
many RTT females. It may be a major determinant of the quality of
daily life of the female and her family [Julu and Witt Engerstr€om,
2005; Smeets et al., 2006;Halbach et al., 2008, 2013; Julu et al., 2008;
Tarquinio et al., 2015]. Neurophysiological research has estab-
lished three cardiorespiratory phenotypes in RTT (forceful, feeble,
and apneustic breathers), and their clinical relevance [Julu and
Witt Engerstr€om, 2005; Smeets et al., 2006; Julu et al., 2008;
Halbach et al., 2011].
Many genotype–phenotype correlation studies have been
published [Huppke et al., 2002; Leonard et al., 2003, 2005; Colvin
et al., 2004; Schanen et al., 2004; Charman et al., 2005; Kerr and
Prescott, 2005; Smeets et al., 2005, 2009; Bebbington et al., 2008,
2012; Neul et al., 2008; Halbach et al., 2012; Cuddapah et al.,
2014]. These studies are based on clinical scoring systems and/or
questionnaires in providing a composite clinical phenotype. To
our knowledge, the published population-based studies did not
have quantitative measures of cardiorespiratory dysfunctions in
Rett syndrome. Cardiorespiratory variables can be measured
objectively in different clinical phenotypes, providing robust
quantitative data for research. It is stated that this has important
implications for life long management and future treatment in
RTT [Julu et al., 2008].
The aim of this collaborative multicenter study is to correlate
for the first time the RTT genotype with the quantitative cardio-
respiratory data obtained by neurophysiological measurement
combined with a clinical severity score.
METHODS
Ethical approval was obtained from theMedical Ethical Committee
at the Maastricht University Medical Center.
Study Design and Participants
In order to achieve a reasonable population size using the brainstem
neurophysiological technique an international multicentre study
was conducted in four European countries from 1999 to 2012. The
sixparticipatingcenterswere:TuscanyRettCentre,VersiliaHospital
(Lucca, Italy), Medical Genetic Unit, Ferrara University Hospital
(Ferrara, Italy), theNational SwedishRettCentre (Fr€os€on, Sweden),
the Rett Expertise Centre Netherlands, Maastricht University
Medical Centre (Maastricht, the Netherlands), Neurodegeneration
and Neuroinflamation at Imperial College (London, United
Kingdom), and InstituteofNeurological Sciences, SouthernGeneral
Hospital (Glasgow, United Kingdom).
The study cohort consisted of a group of 132 well-defined RTT
females with extended clinical, molecular, and neurophysiological
assessment. These females were referred to one of the participatingcenters. Neurophysiological assessment was performed in Italy and
Sweden, each examining 66 RTT females. Diagnosis of RTT was
based on the consensus criteria for RTT [Hagberg et al., 2002; Neul
et al., 2010]. Only females with molecular confirmation were
included. Males with MECP2 related disorders were excluded
from this study.
Molecular Analysis of MECP2
DNA analysis of MECP2 was performed by sequencing
the coding exons and immediately adjacent intronic regions.
Additional Multiplex Ligation-dependent Probe Amplification
analysis ofMECP2 was done to identify large genomic rearrange-
ments. Nomenclature was according to the MECP2A isoform
reference sequence NM_004992.3. Numbering started at the A of
the ATG translation initiation codon. Mutations were classified
by type and localization in the gene (Table I). As to mutation
type, they were classified as missense (single amino acid sub-
stitutions) and truncating mutations (nonsense mutations,
frame shift mutations, and large deletions/duplications). The
following domains were included for mutation localization:
the N-Terminal domain (NT domain), the methyl-CpG-binding
domain (MBD), the transcription repression domain (TRD), and
the C-terminal segment (CTS).
ISS Scoring List
In order to evaluate the clinical severity of the common features in
RTT, a modified version of the International Scoring System was
used (ISS, Table II) [Kerr et al., 2001]. The clinical scoring system
originally consisted of 20 items (ranging from A to T), which were
scored from zero to two; the lower the score, the better the clinical
condition. Based on the high prevalence of gastro-intestinal and
bladder problems in females with RTT, an additional item con-
cerning these problems was added in the adapted ISS (item U).
These 21 items were grouped into five functional domains: Growth
and Development (A–E), Musculoskeletal (F–H), Movement
(I–L), Cortical (M–O), and Autonomic Domain (P–U). The
oro-motor disturbances were included in the Autonomic domain
[Julu and Witt Engerstr€om, 2005].Neurophysiological Assessment
Autonomic monitoring of brainstem function was carried out
using the NeuroScopeTM (Medifit Instruments Ltd, London,
UK). This is a cortico-bulbar neurophysiological method for
TABLE I. Mutation Type and Localization in MECP2
Domain !
Type of mutation # NT (n) MBD (n) TRD (n) CTS (n) Total
Truncating (Nonsense, frame
shift, large deletion)
p.M5fsX (1) p.D90fsX (1) p.R168X (12) p.T327fsX (1) 85
p.R9fsX (9) p.R111fsX (1) p.G237fsX (1) p.K347fsX (1)
p.N126fsX (1) p.G238fsX (1) p.A358fsX (1)
p.Q128X (1) p.R255X (9) p.P362fsX (1)
p.Y141X (2) p.G269fsX (2) p.A378fsX (1)
p.K144fsX (2) p.R270X (11) p.L386fsX (11)




Missense p.R106W (5) p.P225A (1) 47
p.R133 C (14) p.P225 R (1)
p.S134 C (1) p.P302 L (1)




Total 10 44 57 21 132
NT, N-Terminal segment; MBD, Methyl-CpG-Binding Domain; TRD, Transcription Repression Domain; CTS, C-Terminal Segment; n, number of patients (nomenclature according to the MECP2A isoform
reference sequence NM_004992.3).
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simultaneously in real-time and synchronizing the various
autonomic signs. The NeuroScope, a neurophysiology piece
of equipment is used in routine clinical examination in Rett
syndrome [Julu and Witt Engerstr€om, 2005] and other neuro-
developmental disorders like the autistic spectrum disorders
(ASD) [Ming et al., 2016] to monitor brainstem autonomic
functions. The cardiac sensitivity to baroreflex (CSB) was
measured as previously described [Julu et al., 2003], and is
defined as the increase in pulse interval per unit increase in
systolic blood pressure. This quantifies the negative feedback
control of blood pressure (BP) beat by beat. The CSB is
calculated according to the formula previously published
[Julu et al., 2003]. The method detects rapid changes in CSB
in real time within a continuous measurement, facilitating the
evaluations of response latencies. A non-invasive continuous
index of cardiac vagal tone (CVT), described as “pulse synchro-
nized phase shifts in consecutive cardiac cycles” is a form of
cardiac cycle jitter was quantified in real time using the Neuro-
Scope as previously described [Little et al., 1999]. The CVT is
quantified in clinically validated units of a linear vagal scale
(LVS) with zero reference point equivalent to full atropinization
in humans [Julu, 1992a,b]. The electrocardiogram (ECG) for
deriving all the cardiovascular indices was recorded via
three chest leads conforming to Einthoven’s Lead II and the
non-invasive BP waveform was quantified continuously using
volume-clamp photoplethysmography through a finger cuff of
the NexfinTM-Monitoring System (BMEYE, Amsterdam, The
Netherlands) or PortapresTM blood pressure monitor (Finapres
Medical Systems, Amsterdam, The Netherlands). A TCM4 orTCM3 monitor (Radiometer, Copenhagen, Denmark) is used to
quantify the partial pressures of oxygen (pO2) and carbon
dioxide (pCO2) transcutaneous through a special sensor placed
on the abdominal skin in the sub-costal region in the mid-
clavicular line close to the liver and the signal is transmitted live
continuously to the NeuroScope and displayed in real-time
synchronously with all other physiological parameters. Other
raw data were fed into the NeuroScope for further processing
and real-time derivation of the autonomic indices using
VaguSoftTM software (Medifit Instruments Ltd) as follows.
The peaks of blood pressure (BP) waveforms during cardiac
cycles provided values for the systolic pressure (SBP, in mmHg).
The lowest BP before the ejection period of the cardiac cycle is
diastolic BP (DBP, in mmHg) and the arithmetic mean of
arterial pressure during the whole cardiac cycle is mean arterial
pressure (MAP, in mmHg). The instantaneous heart rate (HR,
in bpm) was calculated continuously in real time from the
intervals between consecutive electrocardiographic R-waves
“(R-R intervals, in msec).” Cortical activity was monitored
using electroencephalography (EEG) and synchronized with
autonomic function. A continuous video record time-locked
with the physiological data was kept for behavioral analysis.
The breathing movements measured using a stretch sensitive
plethysmograph placed around the chest at the level of the
xiphisternum were analyzed using the LARS respiratory analysis
software (MediFit Instruments Ltd). The individual breathing
movement was scored for types of rhythm and amplitudes
according to the criteria previously described for Rett syndrome
[Julu and Witt Engerstr€om, 2005]. The total time of each
specific type of breathing movement was compared with the
TABLE II. Modified Version of the ISS Scoring List
International scoring system
Growth and development
A Head circumference during the first year
2 Already below the 3rd percentile at birth
1 Normal at birth but decelerating
0 Normal at birth with no deceleration
B Early developmental progress (birth to 12 months)
2 No or virtually no progress
1 Suboptimal progress
0 Normal progress
C Present head circumference–(percentile/standard
deviations SD)
2 Below 3rd percentile
1 3rd–10th percentile
0 Above 10th percentile
D Weight (kg)
2 Below 3rd percentile
1 3rd–10th percentile
0 Above 10th percentile
E Height (cm)
2 Below 3rd percentile
1 3rd–10th percentile
0 Above 10th percentile
Musculoskeletal
F Muscle tone (also describe)
2 Severe hypotonia, dystonia, or hypertonia











I Gross motor function
2 Cannot walk with support
1 Walking impaired
0 Walks normally
J Hand stereotypy (patting, squeezing, wringing, mouthing)
2 Dominating or constant
1 Mild or intermittent
0 None
K Other involuntary movements (e.g., tremor, dystonia,
chorea, athetosis)
2 Dominating or constant
1 Mild or intermittent
0 None
L Voluntary hand use (e.g., self-feeding)
2 None
1 Reduced or poor
0 Hand use normal
Cortical
M Intellectual disability (¼learning disability, retardation)
2 Apparent profound (infant level)





2 Currently uses no real words with meaning
1 Currently uses some real words with meaning
0 Normal speech
O Epilepsy
2 Uncontrolled or poorly controlled





2 Severe (e.g., feeding aversion; gagging, choking, tube/
button fed)
1 Slight (e.g., delayed chewing, swallowing, on
supplements)
0 None
Q Disturbed awake breathing rhythm (e.g., hyperventilation,
breath holding, panting)
2 Severe, with vacant spells and color changes
1 Mild, without vacant spells and color changes
0 Normal breathing pattern
R Peripheral circulation of extremities
2 Cold or discolored with atrophic changes
1 Cold or discolored without atrophic changes
0 Normal color and temperature of extremities
S Mood disturbance
2 Prominent or disruptive agitation/crying spells
1 Abnormally prone to agitation
0 Normal
T Sleep disturbance
2 Prominent/disruptive day sleeping or night waking
1 Present, not prominent
0 Normal sleep pattern
U Gastro-intestinal and bladder
2 Reflux oesophagitis, severe constipation, or neurogenic
bladder dysfunction
1 Gastrointestinal dysmotility without secondary
complications
0 No signs of gastrointestinal dysmotility or difficulties to
empty bowel or bladder
Adapted from Kerr et al. [2001].
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breathing phenotype determines the cardiorespiratory pheno-
type where Forceful Breathers would have longer duration of
forceful breathing, Feeble Breathers would have longer duration
of weak ineffective breathings and Apneustic Breathers would
have longer duration in apneusis during the whole monitoring
session [Julu and Witt Engerstr€om, 2005].Data Analysis
Data were collected from all centers into a unified, anonymous
database. Clinician experts in RTT made the ISS scoring list.
Baseline brainstem functions were measured during normal
breathing without agitation, with normal blood gases (pCO2














C-terminal deletions 21 16
Total 93 70
HALBACH ET AL. 2305and pO2) and in the absence of epileptiform activity on EEG. We
considered a baseline state of the subjects when there was no
visible contraction of neck muscles and breathing was quiet
(regular breathing curve) with <10% fluctuations about the
means in both blood pressure and heart rate from their peaks
to troughs for at least 10min. Details of the assessment of
brainstem functions to determine cardiorespiratory phenotype
are published elsewhere [Julu and Witt Engerstr€om, 2005; Ming
et al., 2016].
The genotype–phenotype analyses were performed after group-
ing together all mutations of similar types, localizations or putative
biological effect on the MeCP2 protein. Consequently, mutations
were then subdivided into the following five groups: (i) truncating
mutations in the NT andMBD domain, causing loss of function or
disruption of the two functional domains MBD and TRD;
(ii) missense mutations in the MBD domain, giving rise to a
modified or non-functional MBD; (iii) truncating mutations
in the Interdomain and TRD, causing a loss of functional TRD;
(iv) missense mutations in TRD giving rise to a modified or
non-functional TRD; and (v) small truncations in the CTS
leading to protein with an altered C-terminus. A further separate
genotype–phenotype analysis was performed on eight recurrent
mutations, defined as mutations present in at least 5% of the RTT
females in this cohort (Table III).
We used descriptive statistics to analyze mutation types, ISS
scores, and cardiorespiratory data including Valsalva’s manoeu-
vre type of breathing (Valsalva breathing). Linear regression
analysis was used to analyze the relationships among ISS
scores (total and functional domain scores), CVT, HR, and
mutation groups or recurrent mutations. Checks for the nor-
mality assumption were done employing Q–Q plots. If the
normality assumption was in doubt, the analyses were done
by ordinal logistic regression. Relationships among cardiorespi-
ratory phenotypes, Valsalva breathing (present or absent), and
mutation groups or recurrent mutations, were examined using
nominal logistic regression. The mutation groups and the recur-
rent mutations were used as predictor variables through dummy
coding in the regression analyses. Since age may be a confound-
ing factor for the ISS scores and HR, this variable was included asan extra predictor for these outcomes. First a statistical test was
done to check whether there was a relation between mutation
groups or recurrent mutations and the outcome in question. If
present, it was re-examined in a pairwise fashion to determine
which groups differed from each other with respect to the
outcome variable. The level of statistical significance for all tests
was set to a probability value of 0.05, and all analyses were
carried out using SPSS18.RESULTS
The age of the RTT females ranged between 2 and 43 years (mean
age: 12.46 years, SD¼ 9.36). According to the clinical criteria, 74%
(n¼ 98) of the females were typical RTT and 26% (n¼ 34) atypical
RTT.Mutation Analysis
MECP2 mutations were classified by mutation type, localization,
and putative protein function, as shown in Table I. Truncating
mutations were present in 64% (n¼ 85) and missense mutations
in 36% (n¼ 47). Forty-three percent had a mutation affecting the
TRD (n¼ 57), whereas 41% (n¼ 54) had a mutation affecting
the MBD. The mutations localized in the MBD were predomi-
nantly missense mutations (82%), while those affecting in the
TRD were mostly truncating (81%). Half of the truncating
mutations, affecting both the MBD and TRD, were due to a
large deletion of both exon three and most of the coding part of
exon four. Sixteen percent (n¼ 21) displayed a truncating
mutation in the CTS leading to an extensive replacement of
the C-terminus, which is likely to have an unfavorable effect on
the natural protein function due to its putative effect on protein
structure.
Table III shows the recurrent mutations included in this study,
together comprising70%of thepathogenicmutations in this cohort.ISS Scoring List
The mean severity score on the ISS scoring list was 20.7 points
(range 2–36, SD¼ 7.59). Separating the scores into the functional
domains, the mean scores were: Growth and Development, 3.79
points (range 0–8, SD¼ 2.42); Musculoskeletal, 2.54 points (range
0–6, SD¼ 1.84); Movement, 4.76 points (range 1–8, SD¼ 1.59);
Cortical, 4.10 points (range 1–6, SD¼ 1.37); Autonomic, 5.53
points (range 0–12, SD¼ 2.59), respectively.Cardiorespiratory Status of the RTT Cohort
Forty-nine percent were diagnosed as feeble breathers (n¼ 65),
41% as forceful (n¼ 54), and 10% as apneustic (n¼ 13). Valsalva
breathing was present in 62% (n¼ 82), and occurred in all three
cardiorespiratory phenotypes. We assessed both sympathetic and
parasympathetic functions of the autonomic nervous system by
measuring HR and CVT of these females. HR varied between 66
and 172 beats/min (mean rate¼ 99.2, SD¼ 17.4). Mean CVT was
4.50 (range 0.9–13.9, SD¼ 2.53).
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Clinical severity. Total ISS score. The total ISS score did differ
significantly between the different mutation groups (F(df1¼ 4,
df2¼ 126)¼ 3.02, P¼ 0.02). Females with a CTS mutation scored
significantly lower than females with a mutation in the NT domain
or nonsense mutation in the MBD (t¼ 2.53, P¼ 0.01), and with a
nonsense or missense mutation in the TRD (t¼ 3.22, P< 0.01
and t¼ 2.31, P¼ 0.02, respectively).
The total ISS score also differed significantly between the different
recurrent mutations (F(df1¼ 7, df2¼ 83)¼ 4.47, P< 0.001).
Females with a p.R133C, p.R294X, or CTS mutation scored
significantly lower than females with a p.T158M (t¼ 2.32–2.57,
P¼ 0.01–0.02), p.R168X (t¼ 2.70–2.92, P< 0.01), p.R255X
(t¼ 3.54–3.70, P< 0.001–0.01), p.R270X (t¼ 2.55–2.79, P¼ 0.01),
or p.R306C mutation (t¼ 2.05–2.35, P¼ 0.02–0.04).
Growth and development domain. The ISS score in the
Growth and Development domain did differ significantly between
the different mutation groups (F(df1¼ 4, df2¼ 126)¼ 3.22,
P¼ 0.02). Females with a CTS mutation scored significantly lower
than females with a mutation in the NT domain or nonsense
mutation in the MBD (t¼ 3.00, P¼< 0.01), missense mutation in
the MBD (t¼ 2.53, P¼ 0.01), and nonsense or missense mutation
in the TRD (t¼ 2.92, P< 0.01 and t¼ 2.76, P< 0.01, respectively).
The ISS score also differed significantly between the different
recurrent mutations (F(df1¼ 7, df2¼ 83)¼ 4.57, P< 0.001).
Females with a p.R294X or CTS mutation scored significantly
lower than females with a p.T158M (t¼ 3.08,P< 0.01 and t¼ 2.89,
P< 0.01, respectively); p.R168X (t¼ 2.31, P¼ 0.02 and t¼ 2.03,
P¼ 0.05, respectively), p.R255X (t¼ 3.88, P< 0.001 and
t¼ 3.84, P< 0.001, respectively), p.R270X (t¼ 3.10, P< 0.01
and t¼ 2.93, P< 0.01, respectively) or p.R306C mutation
(t¼ 3.00, P< 0.01 and t¼ 2.78, P< 0.01, respectively). Also
females with a p.R133C mutation scored significantly lower
than females with a p.T158M mutation (t¼ 2.00, P¼ 0.05) or
p.R255X mutation (t¼ 2.84, P¼ 0.01).
Musculoskeletal domain. The ISS score in the Musculoskele-
tal domain did not differ significantly among the different muta-
tion groups (F(df¼ 4)¼ 9.42, P¼ 0.051), but did differ
significantly among the different recurrent mutations
(F(df¼ 7)¼ 15.00, P¼ 0.04). Females with a p.R133C or
p.R294X mutation scored significantly lower than females with
a p.T158M (F(df¼ 1)¼ 12.23, P< 0.001 and F(df¼ 1)¼ 9.39,
P< 0.01, respectively), p.R168X (F(df¼ 1)¼ 13.44, P< 0.001
and F(df¼ 1)¼ 10.00, P< 0.01, respectively), p.R255X
(F(df¼ 1)¼ 14.83, P< 0.001 and F(df¼ 1)¼ 11.47, P¼ 0.001,
respectively), p.R270X (F(df¼ 1)¼ 9.19, P< 0.01 and
F(df¼ 1)¼ 6.64, P¼ 0.01, respectively) or p.R306C mutation
(F(df¼ 1)¼ 5.86, P¼ 0.02 and F(df¼ 1)¼ 4.11, P¼ 0.04, respec-
tively). Also females with a CTS mutation scored significantly
lower than females with a p.T158M (F(df¼ 1)¼ 5.84, P¼ 0.02),
p.R168X (F(df¼ 1)¼ 6.38, P¼ 0.01) or p.R255X mutation
(F(df¼ 1)¼ 7.89, P¼ 0.01).
Movement domain. The ISS score in the Movement domain
did not differ significantly among the different mutation groups
(F(df1¼ 4, df2¼ 126)¼ 1.27, P¼ 0.29) or recurrent mutations
(F(df1¼ 7, df2¼ 83)¼ 1.55, P¼ 0.16).Cortical domain. The ISS score in the Cortical domain did
not differ significantly among the different mutation groups
(F(df1¼ 1, df2¼ 5)¼ 12.78, P¼ 0.21) or recurrent mutations
(F(df1¼ 1, df2¼ 8)¼ 14.83, P¼ 0.34).
Autonomic domain. The ISS score in the Autonomic domain
did not differ significantly among the different mutation groups
(F(df1¼ 4, df2¼ 126)¼ 2.11, P¼ 0.08) or recurrent mutations
(F(df1¼ 7, df2¼ 83)¼ 1.93, P¼ 0.08).
Autonomic assessment. Cardiorespiratory phenotype. There
was no significant correlation between cardiorespiratory pheno-
type and groups of mutations (x2(df¼ 8)¼ 4.77, P¼ 0.78).
Excluding the apneustic breathers for the analysis did not change
these results (x2(df¼ 4)¼ 3.37, P¼ 0.50).
Also no significant correlation was seen among the cardiorespi-
ratory phenotypes and recurrent mutations (x2(df¼ 14)¼ 13.42,
P¼ 0.49). Excluding the apneustic breathers for this analysis also
did not change these results (x2(df¼ 7)¼ 8.91, P¼ 0.26).
Valsalva manoeuvre type of breathing. There was no significant
correlation among the presence and absence of Valsalva breathing
and the groups of mutations (x2(df¼ 4)¼ 2.50, P¼ 0.64) or
recurrent mutations (x2(df¼ 7)¼ 10.81, P¼ 0.15).
Cardiac vagal tone (CVT). There was no significant correlation
between CVT and the groups of mutations (F(df1¼ 4,
df2¼ 126)¼ 2.40, P¼ 0.06) or recurrent mutations (F(df1¼ 7,
df2¼ 83)¼ 1.17, P¼ 0.33).
Heart rate (HR). There was no significant correlation between
HR and the groups of mutations (F(df1¼ 4, df2¼ 126)¼ 0.29,
P¼ 0.88) or recurrent mutations (F(df1¼ 7, df2¼ 83)¼ 0.31,
P¼ 0.95).DISCUSSION
This multicenter study was the result of an international collabo-
rative network set up to create a databasewith sufficient numbers of
robust clinical, molecular, and neurophysiological data for further
analyses. The grouping of the mutations in MECP2 was based on
the putative biological effects of these mutations on the MeCP2
protein as explained in our Methods. Despite the minor
methodological differences, the clinical severity and general
genotype–phenotype results were similar to those in previous
studies. We used amodified version of the internationally accepted
clinical scoring system (ISS) to quantify the effects of RTT
on growth, development, and other bodily dysfunctions in our
genotype–phenotype analyses. The ISS provided us with a form of
quantifiable clinical severity of the various bodily dysfunctions in
this RTT cohort, which indeed is comparable with previous
research [Bebbington et al., 2008, 2010; Halbach et al., 2012].
We have elucidated a less severe clinical phenotype in females with
CTS, p.R133C, or p.R294X mutations. However, clinical severity
varies evenwithin one specific type or group ofmutations. Itmeans
genotypes have very limited use for clinical management in RTT.
The main reason for conducting this study was to evaluate
the influence of MECP2 mutation on brainstem instability,
which includes breathing dysrhythmia, so characteristic of RTT.
Breathing dysrhythmia is a major reason for seeking
medical attention and for secondary referral of persons with
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quantitative neurophysiological measurements of brainstem func-
tions, because clinicalmanagement of brainstemautonomic dysfunc-
tion in RTT is a profound challenge. Each cardiorespiratory
phenotype requires a unique and specific clinical approach [Julu
et al., 2008]. In this cohort of RTT females, up to 49% were feeble
breathers, 41% were forceful breathers, and 10% were apneustic
breathers. There is some but little difference in the distribution of
the three cardiorespiratory phenotypes in this cohort compared with
that previously reported [Julu and Witt Engerstr€om, 2005]. This
cohort of RTT confirms that Valsalva breathing is a common
complication of breathing dysrhythmia in RTT, affecting all three
cardiorespiratory phenotypes as previously reported [Julu and Witt
Engerstr€om, 2005]. The wildcat excitatory effects of Valsalva’s
manoeuvre on the autonomic nervous system in general and other
brainstem functions can cause clinical deterioration inRTT [Julu and
Witt Engerstr€om, 2005; Smeets et al., 2006]. Detailed correlation
analyses of the cardiorespiratory data showed that the cardiorespira-
tory phenotypes inRTTare not influencedby geneticmutations. This
provides further proof that the cardiorespiratory phenotypes needs as
much attention in clinical management as the genetic mutations.
The baseline brainstem functions were severely affected in all
RTT females similar to the results in previous studies [Julu et al.,
1997, 2001; Julu and Witt Engerstr€om, 2005]. The mean CVT in
this cohort was lower than the normal mean value in young adults
[Julu, 1992b]. SinceCVT is the only central inhibitory output to the
heart, it is very important in brainstem cardiorespiratory integra-
tion. Its role in rapid cardiovascular responses is very important
and it is a major contributor to integrative inhibition within the
cardiovascular system [Guyenet et al., 1996]. The HR values in this
cohort were within the normal limits for the age group. It implies
that the resting sympathetic tone is within normal limits [Julu et al.,
1997], and not exaggerated above normal as previously thought
[Naidu et al., 1987]. This normal but unrestrained sympathetic
tone due to little or no parasympathetic negative feedback is the
cause of a type of sympatho-vagal imbalance unique to RTT. This
may contribute to the increased sudden deaths of up to 26% of
females with RTT, compared with only 2.3% in the general
population of the same age range [Kerr et al., 1997; Hagberg
et al., 2001]. Although this figure may be overestimated, in
more recent studies sudden unexplained deaths are not specifically
addressed [Laurvick et al., 2006] or the cause of death incompletely
reported [Kirby et al., 2010]. The discussion above and the high ISS
score in the Autonomic Domain both reflect the great impact of
brainstem dysfunction on the clinical severity in RTT. We provide
here sufficient reasons for carers of persons with RTT to seek
medical attention starting early in childhood. This is because
“bedside” clinical evaluation including ISS scoring cannot deter-
mine the contributions of autonomic dysfunction to the clinical
severity in individual cases [Halbach et al., 2012]. In persons with
RTT, objective quantitative clinical and neurophysiological assess-
ment must be done early after diagnosis or promptly following the
onset of brainstem autonomic symptoms. For the moment there is
lack of appropriate neurophysiological facilities for brainstem
assessment in most hospitals and therefore this study is a pledge
tomake themmore available to a larger number of girls andwomen
with RTT.CONCLUSION
This is the first study to use objective and robust data of cardiore-
spiratory variables in the investigation of genotype–phenotype
correlation in RTT. All females with RTT had dysautonomia,
and this was not restricted to nor influenced by one specific group
or single recurrent mutation. The clinical variability within a
specific genetic mutation or within a similar group of mutations
makes genotype–phenotype correlations a difficult task. The robust
and objective information obtained from non-invasive neurophys-
iological evaluation of the brainstem autonomic functions will
contribute to the understanding of the ongoing pathology in RTT
and its life-long management. Although considerable progress is
being made in understanding the mechanisms of autonomic
dysfunction in RTT [Weese-Mayer et al., 2006; Rohdin et al.,
2007; Katz et al., 2009; Lioy et al., 2011; Abdala et al., 2014],
further research is needed for a better understanding of the
pathogenesis of autonomic dysfunctions in this syndrome. This
will facilitate future development of evidence-based management
strategies in RTT.ACKNOWLEDGMENTS
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